Palumbo-Zerr, Katrin
Zerr, Pawel
Distler, Alfiya
Fliehr, Judith
Mancuso, Rossella
Huang, Jingang
Mielenz, Dirk
Tomcik, Michal
Fürnrohr, Barbara G
Scholtysek, Carina
Dees, Clara
Beyer, Christian
Krönke, Gerhard
Metzger, Daniel
Distler, Oliver
Schett, Georg
Distler, Jörg H W
Article History
Received: 14 July 2014
Accepted: 19 November 2014
First Online: 12 January 2015
Competing interests
: O. Distler has consultancy relationships and/or has received research funding from Actelion, Pfizer, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, Roche/Genentech, Medac, Biovitrium, Boehringer Ingelheim, Novartis, 4D Science, Active Biotec, Bayer, Sinoxa, Serodapharm, EpiPharm, GSK, Pharmacyclics and Biogen. J.H.W. Distler has consultancy relationships and/or has received research funding from Actelion, Active Biotech, Array Biopharma, Bayer Pharma, Boehringer Ingelheim, Celgene, GSK, JB Therapeutics, Novartis, Sanofi-Aventis, Sigma Tau and UCB in the area of potential treatments of SSc and is stock owner of 4D Science GmbH. 4D Science has a research cooperation with KaroBio on nuclear receptors as targets for anti-fibrotic therapies. All other authors declare no competing financial interests.